Stay updated on Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial page.

Latest updates to the Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial page
- Check2 days agoChange DetectedA footer release/version update was applied on the study page (updating the visible “Revision” number from v3.5.2 to v3.5.3). This reflects a site change rather than an alteration to the clinical trial details.SummaryDifference0.1%

- Check9 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check38 days agoChange DetectedAdded revision entry v3.5.0 and removed revision entry v3.4.3, affecting only the page's release metadata.SummaryDifference0.1%

- Check45 days agoChange DetectedThe page now displays Revision: v3.4.3, replacing the previous Revision: v3.4.2.SummaryDifference0.1%

- Check73 days agoChange DetectedRevision: v3.4.2 has been added and Revision: v3.4.1 removed; the government funding/operating status notice was deleted.SummaryDifference0.4%

- Check80 days agoChange DetectedA site-wide notice about a lapse in government funding and NIH operations is now displayed, and the page shows a new revision tag (v3.4.1) replacing the previous v3.4.0.SummaryDifference0.5%

Stay in the know with updates to Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial page.